CN118084937A - 双环杂芳族环衍生物 - Google Patents

双环杂芳族环衍生物 Download PDF

Info

Publication number
CN118084937A
CN118084937A CN202410202422.0A CN202410202422A CN118084937A CN 118084937 A CN118084937 A CN 118084937A CN 202410202422 A CN202410202422 A CN 202410202422A CN 118084937 A CN118084937 A CN 118084937A
Authority
CN
China
Prior art keywords
compound
alkyl
mixture
general formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202410202422.0A
Other languages
English (en)
Chinese (zh)
Inventor
杵渊政彦
近藤丈和
落合贡司
西谷洋辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinglin Pharmaceutical Holdings Co ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CN118084937A publication Critical patent/CN118084937A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202410202422.0A 2018-08-21 2019-08-20 双环杂芳族环衍生物 Withdrawn CN118084937A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018154411 2018-08-21
JP2018-154411 2018-08-21
PCT/JP2019/032335 WO2020040104A1 (ja) 2018-08-21 2019-08-20 ２環性ヘテロ芳香環誘導体
CN201980054331.4A CN112752761B (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980054331.4A Division CN112752761B (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Publications (1)

Publication Number Publication Date
CN118084937A true CN118084937A (zh) 2024-05-28

Family

ID=69593150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410202422.0A Withdrawn CN118084937A (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物
CN201980054331.4A Withdrawn - After Issue CN112752761B (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980054331.4A Withdrawn - After Issue CN112752761B (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Country Status (19)

Country Link
US (1) US11952387B2 (https=)
EP (1) EP3842439A4 (https=)
JP (1) JP7309725B2 (https=)
KR (1) KR20210046649A (https=)
CN (2) CN118084937A (https=)
AU (1) AU2019324089B2 (https=)
BR (1) BR112021002515A2 (https=)
CA (1) CA3104054A1 (https=)
CL (1) CL2020003116A1 (https=)
CO (1) CO2021000512A2 (https=)
IL (1) IL278885A (https=)
MX (1) MX2020013039A (https=)
MY (1) MY200452A (https=)
PH (1) PH12020551991A1 (https=)
SA (1) SA520420914B1 (https=)
SG (1) SG11202012616RA (https=)
TW (1) TWI811428B (https=)
WO (1) WO2020040104A1 (https=)
ZA (1) ZA202101146B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT65486B (en) 1975-08-28 1978-03-24 Lilly Co Eli Process for the preparation of carbonil-substituted 1-sulfonylbenzimidazoles
JPH0649066B2 (ja) 1985-02-14 1994-06-29 積水化学工業株式会社 医療用粘着シ−トもしくはテ−プ
FR2687574B1 (fr) * 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JPH07188017A (ja) 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JPH11106340A (ja) * 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6258831B1 (en) 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
HUE025976T2 (en) 2007-09-27 2016-05-30 Fund Centro Nac De Investig Oncologicas Carlos Iii Imidazolothiadiazoles for use as protein kinase inhibitors
AU2009275544B2 (en) * 2008-07-29 2013-09-12 Merck Patent Gmbh Imidazothiadiazoles derivatives
US8629153B2 (en) * 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
NZ595674A (en) 2009-04-02 2012-12-21 Ct Nac Investigaciones Oncologicas Cnio Imidazo[2,1-b][1,3,4]thiadiazole derivatives
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
WO2013052845A1 (en) 2011-10-05 2013-04-11 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
JP6298830B2 (ja) 2012-12-20 2018-03-20 ユーシービー バイオファルマ エスピーアールエル 治療用に活性なピラゾロ−ピリミジン誘導体
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
JP6509238B2 (ja) 2014-01-22 2019-05-08 キュロヴィル・アクチボラグ 治療に有用なピラゾロ［１，５−ａ］ピリミジン−７−アミン誘導体
US10471028B2 (en) 2014-06-13 2019-11-12 University Of Rochester Small molecule efflux pump inhibitors
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
AU2016284638B2 (en) 2015-06-24 2020-01-23 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
US20190048421A1 (en) 2015-09-21 2019-02-14 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US20190358196A1 (en) 2016-07-27 2019-11-28 Henry C. Lowe Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Also Published As

Publication number Publication date
IL278885A (en) 2021-01-31
US11952387B2 (en) 2024-04-09
JPWO2020040104A1 (ja) 2021-08-12
JP7309725B2 (ja) 2023-07-18
SG11202012616RA (en) 2021-02-25
SA520420914B1 (ar) 2023-12-25
MX2020013039A (es) 2021-02-26
TW202021971A (zh) 2020-06-16
US20220332730A1 (en) 2022-10-20
CA3104054A1 (en) 2020-02-27
CO2021000512A2 (es) 2021-01-29
CN112752761A (zh) 2021-05-04
ZA202101146B (en) 2022-07-27
BR112021002515A2 (pt) 2021-07-27
EP3842439A4 (en) 2022-04-27
MY200452A (en) 2023-12-27
KR20210046649A (ko) 2021-04-28
AU2019324089A1 (en) 2020-12-10
CL2020003116A1 (es) 2021-04-16
EP3842439A1 (en) 2021-06-30
PH12020551991A1 (en) 2021-08-02
WO2020040104A1 (ja) 2020-02-27
AU2019324089B2 (en) 2024-06-13
CN112752761B (zh) 2024-03-29
TWI811428B (zh) 2023-08-11

Similar Documents

Publication Publication Date Title
EP3464278B1 (en) Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
TW200800182A (en) Nitrogen-containing heterocyclic derivatives substituted by ring-type groups
JP5604424B2 (ja) アポトーシス促進剤ａｂｔ−２６３の調製のための方法
TW201136919A (en) Inhibitors of hepatitis C virus NS5B polymerase
WO2016203112A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
JP2022046542A (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
JP2013532164A (ja) トロンビン特異的インヒビターを調製する方法
CN102123999B (zh) 制备食欲素受体拮抗剂的方法
JP7615257B2 (ja) ２－（２，６－ジクロロフェニル）－１－［（１ｓ，３ｒ）－３－（ヒドロキシメチル）－５－（３－ヒドロキシ－３－メチルブチル）－１－メチル－３，４－ジヒドロイソキノリン－２（１ｈ）－イル］エテノンの調製のための方法および中間体
CZ47393A3 (en) Inodole and indazole derivatives, their preparation and use
WO2022232949A1 (en) Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb)
JP2026062914A (ja) Ｇ９ａ阻害剤
CN112752761B (zh) 双环杂芳族环衍生物
EP1940823A2 (fr) Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique
EP0189771A2 (en) (Isoxazol-3-yl)arylmethanones, a process for their preparation and their use as medicaments
CN1935779A (zh) N－(n－苯甲酰基－苯丙氨酰基)－苯丙氨酸二肽衍生物及其制备方法和用途
RU2798838C2 (ru) Бициклическое гетероароматическое кольцевое производное
CN106661009B (zh) 抗肠病毒71噻二唑烷衍生物
HK40051492A (en) Bicyclic heteroaromatic ring derivative
CN107709318B (zh) 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
CN102924454A (zh) 恩替卡韦的合成方法
CN107245023B (zh) 一种选择性脱氧氟化试剂及方法
TW202402761A (zh) 製備shp2抑制劑的方法
CN104418707B (zh) 一种天然产物补骨脂酚及其对映体的不对称合成方法
CN111094270A (zh) 光学活性吡咯烷化合物及其制造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Japan

Address after: 3-7 Otemachi 1-chome, Chiyoda ku, Tokyo, Japan

Applicant after: KYORIN PHARMACEUTICAL Co.,Ltd.

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant before: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region before: Japan

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241025

Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant after: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region after: Japan

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20240528